$BRSL

Brainsway's Q4 earnings call highlighted a stronger than expected revenue growth, driven by increased demand for their non-invasive brain stimulation technology. The company reported a larger than anticipated increase in patient treatments and expanded its market reach through strategic partnerships. Additionally, management provided optimistic guidance for the upcoming quarters, expecting continued growth in both revenue and treatment numbers. However, there were concerns regarding rising competition in the neuromodulation space, which could impact market share. Investors reacted positively to the overall performance and guidance, although some were cautious about competitive pressures.